Diligence memo · auto-generated · as of July 2, 2026

Hera Testing Laboratories, Inc.

Hera Testing Laboratories, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Hera Testing Laboratories, Inc. operates in Biotechnology, based in LEXINGTON.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Hera Testing Laboratories, Inc. has raised $3.4M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $1.1M on 2015-02-18.

Most recent recorded round closed around 2020-07-30.

Valuation (modeled)modeled

Provath models Hera Testing Laboratories, Inc. at approximately $45M (range $769K–$349M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.71× the median modeled value of Seed Biotechnology companies in 2019–2021 (186 peers) — value vs value, same stage and era. Within the normal band (71% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 22 months.

Last raise 5.9 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 2.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 36% of Biotechnology peers (4293 compared).

Modeled value ranks above 43% of those peers.

Closest niche peers: Novo Biosciences, Inc., Entac Medical, Inc., ReGelTec, Inc., Korro Bio, Inc., TamuroBio Inc..

Peoplefiled

7 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.